Welcome to Advanced Search

Pharmacological inhibition of MYC to mitigate chemoresistance in preclinical models of squamous cell carcinoma

Model Organisms：小鼠 Product & Service：- Research field：

Preclinical characterization of Sintilimab, a fully human anti-PD-1 therapeutic monoclonal antibody for cancer

Model Organisms：Mouse Product & Service：PD-1 Research field：Cancer Immunotherapy

Preclinical evaluation of the theranostic potential of 89Zr/177Lu-labeled anti-TROP-2 antibody in triple-negative...

Model Organisms：小鼠 Product & Service：- Research field：

Chemokine Receptors CCR6 and PD1 Blocking scFv E27 Enhances Anti-EGFR CAR-T Therapeutic Efficacy in a Preclinical...

Model Organisms：小鼠 Product & Service：M-NSG Research field：Non-Small Cell Lung Carcinoma

TYM-3-98, a novel selective inhibitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B-cell...

Model Organisms：小鼠 Product & Service：- Research field：

Join Our Webinar: Applications of Humanized Mouse Models in Preclinical Research

Humanized mouse models preclinical research targeted therapies webinar oncology drug development preclinical therapeutic advancements immune system models animal modeling services

Join GenoBioTX's webinar on July 25th to explore the latest advancements in humanized mouse models for preclinical research. Learn how these models are transforming targeted therapy development across various diseases. Featuring expert insights from Dr. Derek Reznik, discover the generation and application of humanized immune system models in oncology drug development. Don't miss this opportunity to enhance your knowledge in cutting-edge preclinical therapeutic advancements. Register now!

Webinar on Advances in Antibody-Drug Conjugates (ADCs) Development & Preclinical Models

Antibody-Drug Conjugates ADC Development Preclinical Models Targeted Cancer Therapies GenoBioTX ADC Webinar Biopharma Research Oncology Biochemistry Cancer Treatment Preclinical Evaluation Monoclonal Antibodies Small Molecule Drugs

Join us for a webinar on June 26th, 2024, exploring the development and preclinical evaluation of Antibody-Drug Conjugates (ADCs). Learn from Dr. Hua Wei, VP of the Industrial Clients Department at GenoBioTX, about ADC components, mechanisms, historical evolution, and future directions.

Advancing Cancer Therapy: Harnessing In Vivo Tumor Models for Breakthrough Drug Development

Cancer therapy advancements In vivo tumor models Preclinical cancer research Drug development in oncology Gene-modified cell lines Immuno-oncology Tumor modeling for drug discovery Cancer drug development Animal modeling services Cancer drug preclinical models

Join us for an insightful webinar exploring the critical role of in vivo tumor models in advancing cancer drug therapy. We will provide an overview of the diverse tumor models developed by our company, highlighting case studies demonstrating their effectiveness in preclinical cancer research. The session will delve into the comprehensive use of gene-modified cell lines and genetically modified spontaneous mouse models, showcasing their application in mimicking human cancer biology. We will conclude with a brief introduction to our company and our commitment to accelerating cancer drug development through innovative animal modeling services.

Workshop：Progress and Advances in Preclinical immuno-Oncology Research

SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

Harnessing the Power of the Cre-loxP System: Benefits, Challenges, and Applications

This webinar will introduce the Cre-loxP system, a powerful genetic tool that has revolutionized biological research by allowing for conditional gene knockout, knockdown, and overexpression. We will cover the history of the genetic recombination systems, discuss how they enable precise control of gene expression in specific cell types or at specific developmental stages, and present GenoBioTX’s genetically modified models utilizing this method.